Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.034 EUR -5.25% Market Closed
Market Cap: 143m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Nanobiotix SA
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nanobiotix SA
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Nanobiotix SA
PAR:NANO
Long-Term Debt
€43.7m
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
45%
Valneva SE
PAR:VLA
Long-Term Debt
€187.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Long-Term Debt
€68.5m
CAGR 3-Years
9%
CAGR 5-Years
49%
CAGR 10-Years
33%
G
Genfit SA
PAR:GNFT
Long-Term Debt
€59.8m
CAGR 3-Years
-3%
CAGR 5-Years
-19%
CAGR 10-Years
48%
Inventiva SA
PAR:IVA
Long-Term Debt
€46.8m
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Long-Term Debt
€86.2m
CAGR 3-Years
90%
CAGR 5-Years
45%
CAGR 10-Years
22%
No Stocks Found

Nanobiotix SA
Glance View

Market Cap
142.9m EUR
Industry
Biotechnology

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

NANO Intrinsic Value
4.297 EUR
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Nanobiotix SA's Long-Term Debt?
Long-Term Debt
43.7m EUR

Based on the financial report for Jun 30, 2024, Nanobiotix SA's Long-Term Debt amounts to 43.7m EUR.

What is Nanobiotix SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
45%

Over the last year, the Long-Term Debt growth was 4%. The average annual Long-Term Debt growth rates for Nanobiotix SA have been 2% over the past three years , 2% over the past five years , and 45% over the past ten years .

Back to Top